Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRSP | CRISPR Therapeutics AG

Index- P/E- EPS (ttm)-5.30 Insider Own0.50% Shs Outstand79.09M Perf Week-9.45%
Market Cap3.69B Forward P/E- EPS next Y-6.81 Insider Trans-15.71% Shs Float78.36M Perf Month-9.31%
Income-415.90M PEG- EPS next Q-1.96 Inst Own69.00% Short Float / Ratio17.97% / 14.77 Perf Quarter-18.26%
Sales170.10M P/S21.68 EPS this Y-278.00% Inst Trans-0.04% Short Interest14.08M Perf Half Y6.17%
Book/sh22.96 P/B1.99 EPS next Y-43.40% ROA-18.40% Target Price86.00 Perf Year-31.28%
Cash/sh21.96 P/C2.09 EPS next 5Y- ROE-22.20% 52W Range38.94 - 72.00 Perf YTD12.67%
Dividend- P/FCF- EPS past 5Y-37.40% ROI-35.90% 52W High-36.39% Beta1.61
Dividend %- Quick Ratio14.00 Sales past 5Y-50.70% Gross Margin- 52W Low17.62% ATR1.80
Employees458 Current Ratio14.00 Sales Q/Q44203.80% Oper. Margin- RSI (14)34.75 Volatility3.68% 3.35%
OptionableYes Debt/Eq0.00 EPS Q/Q59.00% Profit Margin- Rel Volume0.49 Prev Close46.06
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume953.35K Price45.80
Recom2.30 SMA20-7.65% SMA50-11.37% SMA200-11.85% Volume279,722 Change-0.56%
Date Action Analyst Rating Change Price Target Change
Aug-17-23Upgrade Citigroup Neutral → Buy
May-30-23Initiated William Blair Outperform $75
Apr-13-23Initiated Cantor Fitzgerald Overweight $72
Mar-21-23Initiated Bernstein Mkt Perform $44
Mar-17-23Initiated Bryan Garnier Buy $70
Mar-07-23Initiated Robert W. Baird Neutral $46
Oct-11-22Initiated Morgan Stanley Underweight $37
Aug-09-22Downgrade Barclays Overweight → Equal Weight $99 → $88
Jun-23-22Downgrade Evercore ISI Outperform → In-line $66 → $60
Jun-17-22Initiated BMO Capital Markets Outperform $98
Sep-21-23 06:15PM
05:30AM
Sep-20-23 07:21AM
Sep-18-23 05:00AM
Sep-16-23 09:21AM
06:15PM Loading…
Sep-15-23 06:15PM
10:07AM
05:49AM
Sep-14-23 06:15AM
Sep-12-23 12:48PM
07:00AM
06:00AM
Sep-08-23 01:27PM
Sep-07-23 08:30AM
Sep-06-23 11:30AM
06:17AM Loading…
06:17AM
Sep-05-23 06:00AM
Sep-02-23 07:38AM
Aug-30-23 08:00AM
Aug-26-23 06:55AM
Aug-24-23 10:29AM
Aug-22-23 10:00AM
Aug-18-23 01:00AM
Aug-16-23 09:32AM
Aug-14-23 06:15AM
Aug-12-23 08:07AM
07:30AM
Aug-11-23 09:45AM
Aug-09-23 04:00PM
09:30AM
07:05AM Loading…
07:05AM
Aug-08-23 04:23PM
12:14PM
11:09AM
Aug-07-23 06:57PM
05:15PM
04:01PM
11:01AM
Aug-02-23 04:15PM
03:17PM
09:16AM
Aug-01-23 09:00PM
Jul-31-23 05:30AM
Jul-27-23 12:38PM
Jul-25-23 06:00PM
Jul-22-23 09:45AM
Jul-21-23 08:15AM
05:30AM
Jul-19-23 04:14PM
Jul-18-23 06:15PM
Jul-15-23 05:14AM
Jul-13-23 09:24PM
09:30AM
09:30AM
08:24AM
Jul-12-23 06:00AM
Jul-11-23 06:00AM
Jul-09-23 05:21AM
Jul-06-23 07:12PM
Jul-05-23 08:24PM
07:36AM
Jul-03-23 06:00PM
05:30AM
Jul-02-23 02:00PM
Jun-29-23 09:53AM
08:14AM
Jun-28-23 07:45AM
05:30AM
Jun-27-23 10:15AM
Jun-26-23 06:00PM
Jun-25-23 06:07AM
Jun-21-23 09:09PM
09:45AM
07:15AM
05:30AM
Jun-20-23 06:00PM
08:25AM
Jun-18-23 05:52AM
Jun-17-23 09:15AM
Jun-16-23 03:30AM
Jun-14-23 11:40AM
09:45AM
Jun-13-23 09:00AM
05:30AM
Jun-12-23 07:30AM
Jun-09-23 04:12PM
01:37PM
01:23PM
05:50AM
03:01AM
Jun-08-23 07:23PM
11:30AM
06:00AM
Jun-07-23 11:30AM
Jun-06-23 05:30AM
May-31-23 07:45AM
May-30-23 12:31PM
06:49AM
May-28-23 10:15AM
May-27-23 06:14AM
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerMay 30Option Exercise19.1225,000478,000412,377Jun 01 05:44 PM
Kulkarni SamarthChief Executive OfficerMay 30Sale64.8825,0001,621,894387,377Jun 01 05:44 PM
Kulkarni SamarthChief Executive OfficerApr 25Option Exercise19.1225,000478,000412,377Apr 27 05:37 PM
Kulkarni SamarthChief Executive OfficerApr 25Sale50.6725,0001,266,638387,377Apr 27 05:37 PM
Kulkarni SamarthChief Executive OfficerMar 29Option Exercise19.1225,000478,000412,377Mar 31 05:49 PM
Kulkarni SamarthChief Executive OfficerMar 29Sale44.4625,0001,111,504387,377Mar 31 05:49 PM
Kulkarni SamarthChief Executive OfficerFeb 27Option Exercise19.1225,000478,000400,988Mar 01 06:11 PM
Kulkarni SamarthChief Executive OfficerFeb 27Sale48.2525,0001,206,243375,988Mar 01 06:11 PM
Kulkarni SamarthChief Executive OfficerJan 27Option Exercise19.1225,000478,000394,111Jan 31 05:34 PM
Kulkarni SamarthChief Executive OfficerJan 27Sale51.4725,0001,286,798369,111Jan 31 05:34 PM
Kulkarni SamarthChief Executive OfficerDec 28Option Exercise19.1225,000478,000394,111Dec 30 05:33 PM
Kulkarni SamarthChief Executive OfficerDec 28Sale40.9325,0001,023,290369,111Dec 30 05:33 PM
Kulkarni SamarthChief Executive OfficerDec 06Option Exercise1.8158,233105,402369,111Dec 08 05:35 PM
Kulkarni SamarthChief Executive OfficerNov 28Option Exercise19.1225,000478,000315,279Nov 30 05:36 PM
Kulkarni SamarthChief Executive OfficerNov 28Sale54.0325,0001,350,827290,279Nov 30 05:36 PM
Kulkarni SamarthChief Executive OfficerOct 26Option Exercise16.8425,000421,016315,279Oct 28 05:43 PM
Kulkarni SamarthChief Executive OfficerOct 26Sale54.8125,0001,370,191290,279Oct 28 05:43 PM
Kulkarni SamarthChief Executive OfficerSep 28Option Exercise16.2125,000405,250315,279Sep 30 05:42 PM
Kulkarni SamarthChief Executive OfficerSep 28Sale64.6125,0001,615,160290,279Sep 30 05:42 PM